What was filed
Lupin told the exchanges that VISUfarma B.V., its wholly owned Netherlands subsidiary, has signed an Exclusive License Agreement with U.S.-based Visus Therapeutics, Inc. — a subsidiary of Tenpoint Therapeutics — to commercialize YUVEZZI, a proprietary ophthalmic product indicated for presbyopia in adults. The rights cover the European Union, the United Kingdom, Switzerland, Norway and Iceland.
Under the agreement VISUfarma holds exclusive rights to undertake regulatory activities, commercialization, marketing, promotion, distribution and sale of the product in these markets. The filing describes YUVEZZI as the first and only FDA-approved once-daily, dual-agent eye drop for presbyopia, combining carbachol and brimonidine tartrate.
How the deal is structured
The money side of the arrangement has two parts, the company said: a strategic equity investment in Visus made through a SAFE (Simple Agreement for Future Equity) instrument, and a series of regulatory and commercial milestone payments contingent on specified submissions, approvals and commercial thresholds. Beyond these, the agreement provides for royalty payments based on net sales and additional sales-milestone payments.
The licence runs on a country-by-country basis until the twentieth anniversary of first commercial sale in each country, after which VISUfarma may renew in five-year successive periods at its sole discretion. Lupin noted the transaction is not a related-party transaction and that no promoter or group company has an interest in it.
Why it matters to a holder
Lupin frames the arrangement as an extension of its Specialty Care strategy, building on its earlier acquisition of VISUfarma to broaden its European vision-care franchise. The disclosure adds a defined asset to Lupin's specialty portfolio in named developed markets, with the bulk of the headline consideration tied to milestones and equity rather than paid upfront. The filing does not quantify expected revenue or the timing of commercial launch in the licensed territories.